This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma.

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene-sponsored or Celgene alliance partner-sponsored study.

This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) [FOLFIRI/FOLFOX and bevacizumab] as second-line treatment of advanced colorectal cancer patients.

In Parts A and B, approximately 150 evaluable adult advanced colorectal cancer patients with measurable disease who have radiographically progressed during or following 1 line of systemic treatment will be enrolled in the study.

This study is comparing the efficacy of the study drug RO7198457 versus “watchful waiting” in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.

The purpose of this study is to test the efficacy of the combination of the study drugs tazemetostat with mosunetuzumab and see what effects it has on untreated follicular lymphoma. An additional purpose of this study is to understand what side effects people may have when they receive both drugs together.

This is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration resistant prostate cancer, melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled.

This clinical trial is for men and women with early-stage esophageal cancer (EC) or gastroesophageal junction cancer (GEJC) who are currently receiving adjuvant nivolumab prior to and independently of participation in the study.

The purpose of this study is to learn more about patients with EC or GEJC who have started with nivolumab treatment and about the use and the effects of nivolumab in clinical practice. For this reason, BMS is conducting this study to collect additional information about:

This clinical trial is for men and women who have myeloid disease, a disease caused by blood cells that are not working properly.
   

Doctors know a lot about performing prostate surgeries. However, we are always trying to learn more and improve our skills for our patients' benefit. We want to try and make prostate surgeries safer, with fewer side effects for the patient, and look for a better way to remove cancer. In this study, we will monitor if there are problems after a participant's surgery. We will also document the results of the surgery and patient-reported quality of life.

The purpose of this registry is to collect subject data, medical information, treatment data, and outcomes of patients treated by the Head and Neck Surgery Division in the Department of Otolaryngology at New York Presbyterian Hospital/Weill Cornell Medical Center. The intended use of this database is for research related to the evaluation, management, and outcomes of patients who were treated by our providers.